XML 51 R38.htm IDEA: XBRL DOCUMENT v3.23.1
SHAREHOLDERS' EQUITY (Tables)
12 Months Ended
Dec. 31, 2022
Share-based Payment Arrangement, Noncash Expense [Abstract]  
Schedule of Stock Options Granted
   
Year ended
December 31, 2022
 
   
Number
of options
   
Weighted
average
exercise
price
   
Weighted average remaining contractual term
(in years)
   
Aggregate
intrinsic
value
 
                         
Outstanding at beginning of year
   
5,186,446
   
$
3.40
     
4.01
   
$
534
 
Granted
   
1,478,696
     
2.33
                 
Exercised
   
(226,116
)
   
1.81
                 
Forfeited or expired
   
(1,133,294
)
   
4.42
                 
                                 
Outstanding at end of the year
   
5,305,732
   
$
2.95
     
3.83
   
$
19
 
                                 
Options exercisable at end of the year
   
2,735,334
   
$
2.99
     
2.86
   
$
3
 
                                 
Vested and expected to vest
   
4,052,658
   
$
2.96
     
3.50
   
$
10
 
Schedule of RSUs Granted
   
Year ended
December 31, 2022
 
   
Number of RSUs
   
Aggregate intrinsic
value
 
             
Unvested at beginning of year
   
699,679
   
$
1,805
 
Granted
   
1,805,163
         
Vested
   
(195,969
)
       
Forfeited
   
(200,534
)
       
                 
Unvested at end of the year
   
2,108,339
   
$
4,027
 
                 
Vested and expected to vest
   
1,564,025
   
$
2,987
 
Schedule of Equity-Based Compensation Expense
   
Year ended
December 31,
 
   
2020
   
2021
   
2022
 
                   
Cost of revenues
 
$
110
   
$
289
   
$
587
 
Research and development, net
   
243
     
236
     
405
 
Sales and marketing
   
545
     
700
     
1,355
 
General and administrative
   
764
     
1,337
     
1,213
 
                         
Total share-based compensation expenses
 
$
1,662
   
$
2,562
   
$
3,560